The EU HTA process should be considered a learning system
Interview in Market Access & Health Policy 01/2024
Interview with Heike Kielhorn (2024)
market access & health policy 01/2024
The new EU HTA regulation defines for the first time the benefit assessment of new therapies at European level. This process will be conducted parallel to European approval. Heike Kielhorn, founder and managing director of SKC, explains the challenges facing the pharmaceutical industry as a result of the EU HTA regulation. However, despite all the unanswered questions and tasks that need to be solved, Kielhorn also sees numerous advantages for both pharmaceutical companies and patients in the European Union.
Download
Here you can download the whole interview (only in German language) free of charge.
The EU HTA process should be considered a learning system
PDF 539 kB Download
